Related content

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer

By Claret Laurent   Lu Jian-Feng   Sun Yu-Nien   Bruno René  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1141-1149

Springer Publishing Company

Access to resources Recommend Favorite

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer

By Sculier J.P.   Paesmans M.   Thiriaux J.   Lecomte J.   Bureau G.   Giner V.   Koumakis G.   Lafitte J.J.   Berchier M.C.   Alexopoulos C.G.   Zacharias C.   Mommen P.   Ninane V.   Klastersky J.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1314-1319

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

By Hsyu Poe-Hirr   Mould Diane   Upton Richard   Amantea Michael  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 209-218

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

By Trocòniz Iñaki   Garrido María   Segura Cristina   Cendrós Josep-María   Principe Paola   Peraire Concepción   Obach Rosendo  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 727-735

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy

By            

Oncology Letters, Vol. 2, Iss. 6, 2011-01 ,pp. : 1033-1040

Spandidos Publications

Access to resources Recommend Favorite